Recent Transactions

02-Mar-98
$400 million
Italy flag
Target: 

Olsy SpA (Olivetti SpA)

United States flag
Acquiror: 
Wang Laboratories Inc.

Advised Wang on its acquisition of Olsy, the systems and solutions division of Olivetti, for a combination of cash and securities.

30-Jul-01
$117 million
United Kingdom flag
Target: 

Kymata Ltd.

France flag
Acquiror: 
Alcatel Optronics

Advised Kymata Ltd, the Scottish manufacturer of optical components, on its sale to Alcatel Optronics of France.

24-Mar-06
$21.2 billion
Germany flag
Target: 

Schering AG

Germany flag
Acquiror: 
Bayer AG

Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany

19-Dec-06
$270 million
United States flag
Target: 

Brion Technologies, Inc.

Netherlands flag
Acquiror: 
ASML Holding N.V.

Advised ASML Holding N.V., a leading provider of lithography systems for the semiconductor industry, on its acquisition of Brion Technologies, Inc.

22-Jan-08
$3.4 billion
United States flag
Target: 

Ventana Medical Systems, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment

05-Aug-08
$NA
Germany flag
Target: 

BARTEC Group

Switzerland flag
Acquiror: 
Capvis

Advised Capvis, a leading Swiss private equity firm, on its acquisition of the BARTEC Group, a leading European provider of industrial safety technology, from Allianz Capital Partners, the captive private equity arm of Allianz AG, and the Barlian family (founding family)

15-Sep-08
$189 million
Belgium flag
Target: 

Fermat International

United States flag
Acquiror: 
Moody’s Corporation

Advised Moody’s Corporation on its acquisition of Fermat International, a leading provider of risk and performance management software to the global banking sector

01-Oct-08
$53 million
Sweden flag
Target: 

Biotage (Biosystems division)

Netherlands flag
Acquiror: 
Qiagen NV

Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research

12-Mar-09
$46.9 billion
United States flag
Target: 

Genentech, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company

01-May-09
$65 million
Singapore flag
Target: 

euNetworks Group Limited

Advised euNetworks Group Ltd, a Singapore listed operator of a fibre telecommunications network in Europe, on a repurchase at a discount of the majority of its outstanding convertible bonds, financed by a placement and rights issue

09-Nov-09
$327 million
United States flag
Target: 

Enzon Pharmaceuticals, Inc.

Italy flag
Acquiror: 
Sigma-Tau Pharmaceuticals

Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company

04-Dec-09
$NA
Germany flag
Target: 

Verivox Holding Limited

United Kingdom flag
Acquiror: 
Oakley Capital Private Equity LP

Advised the shareholders of Verivox Holdings Limited, comprising Independent News & Media plc and the founders and joint CEOs of Verivox, on the sale of 51% in Verivox, Germany’s leading price comparison website for energy and telecommunications services, to Oakley Capital Private Equity

21-Sep-10
$234 million
Israel flag
Target: 

Taro Pharmaceutical Industries

India flag
Acquiror: 
Sun Pharmaceutical Industries Ltd.

Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company

15-Dec-10
$12.9 billion
U.S.A., Swiss flags
Target: 

Alcon, Inc.

Switzerland flag
Acquiror: 
Novartis AG

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

26-Mar-12
$513 million
United States flag
Target: 

ISTA Pharmaceuticals, Inc.

United States flag
Acquiror: 
Bausch + Lomb, Inc.

Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company

09-Jul-12
$4.7 billion
Netherlands flag
Target: 

ASML Holding NV (minority stake)

U.S.A., Taiwan, South Korea flags
Acquiror: 
Customers including Intel Corporation, TSMC and Samsung Electronics

Advised the Supervisory Board of ASML on the establishment of a Customer Co-Investment Program including the issue of 23% equity stake and $1.7 billion of R&D funding

01-Aug-12
$4.0 billion
South Africa, Switzerland flags
Target: 

Mediclinic International Limited

Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa

17-Oct-12
$2.6 billion
United States flag
Target: 

Cymer, Inc.

Netherlands flag
Acquiror: 
ASML Holding NV

Advised ASML Holding NV, a leading provider of lithography systems for the semiconductor industry, on its acquisition of Cymer, Inc., a leading supplier of lithography light sources used by chipmakers to manufacture advanced semiconductor devices

20-May-13
$8.5 billion
Ireland flag
Target: 

Warner Chilcott, plc

United States flag
Acquiror: 
Actavis, Inc.

Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc

18-Feb-14
$25.1 billion
United States flag
Target: 

Forest Laboratories Inc.

Ireland flag
Acquiror: 
Actavis plc

Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.

05-Aug-14
$1.3 billion
U.S.A., Germany flags
Target: 

Siemens Health Services

United States flag
Acquiror: 
Cerner Corporation

Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.

11-Aug-14
$NA
United States flag
Target: 

MannKind Corporation

France flag
Acquiror: 
Sanofi

Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.

29-May-15
$4.1 billion
United Kingdom flag
Target: 

Telecity Group plc

United States flag
Acquiror: 
Equinix, Inc.

Advised Telecity Group plc, Europe’s leading provider of premium carrier-neutral data centres, on a recommended cash and share offer from Equinix, Inc. a leading US provider of colocation data centre services globally

08-Jun-15
$45 million
Canada flag
Target: 

Aralez Pharmaceuticals Inc.

Canada flag
Acquiror: 
QLT Inc.

Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.

27-Jul-15
$40.5 billion
Ireland flag
Target: 

Allergan Generics

Israel flag
Acquiror: 
Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

Pages

show all